Who Owns Tasigna?

Novartis publishes annual sustainability reports covering environmental impact, access to healthcare, and ethical business practices. The company has committed to achieving carbon neutrality by 2030 for its own operations and has set targets for reducing water consumption and waste across its manufacturing facilities.

A significant ethical issue for Tasigna and other specialty pharmaceuticals is access and affordability. Before generic competition, Tasigna's high price (approximately $15,000-$18,000 per month in the United States) created substantial access barriers. Novartis offered patient assistance programs in some markets, but many patients struggled with out-of-pocket costs. The availability of generic nilotinib since 2025 has improved access, though the drug remains expensive in markets where generics have not yet launched.

Novartis has also faced scrutiny over its patent strategies. The company's efforts to extend market exclusivity through secondary patents, including the patent covering administration with apple sauce, drew criticism from generic manufacturers and patient advocacy groups who argued that such patents delayed access to more affordable generic versions. The settlement of the apple sauce patent dispute at the Unified Patent Court in 2025 resolved one such conflict, though the confidential terms mean the impact on generic access is unclear.

Tasigna has been associated with several safety concerns and legal disputes throughout its market history.

Cardiovascular Safety Concerns: Tasigna carries warnings about cardiovascular side effects, including QT prolongation (an abnormal heart rhythm that can lead to sudden death), sudden cardiac death, and vascular occlusive events. The FDA required Novartis to include boxed warnings about these risks. Clinical studies and post-marketing surveillance identified an increased risk of cardiovascular events in patients taking Tasigna compared to those taking imatinib. Novartis updated the drug's label and implemented risk mitigation measures, but the cardiovascular safety profile remains a clinical consideration when choosing CML treatments.

Patent Litigation: Novartis engaged in extensive patent litigation to protect Tasigna from generic competition. The company filed cases against multiple generic manufacturers in various jurisdictions. In Europe, the Unified Patent Court case between Novartis and Accord Healthcare over the apple sauce administration patent was settled in 2025. In the United States, patent disputes continued even as generics launched, with some patents (such as U.S. Patent 8,163,904 covering nilotinib salts) not expiring until 2028-2029. However, FDA approval of generic versions and subsequent launches proceeded despite ongoing patent disputes.

Pricing and Access: Tasigna's high price drew criticism from patient advocacy groups and policymakers. At approximately $15,000-$18,000 per month in the United States, the drug placed significant financial burden on patients and healthcare systems. Critics argued that the pricing was disproportionate, particularly given that CML is a chronic condition requiring long-term treatment. The launch of generic versions in 2025 has begun to address these concerns, but the branded drug's pricing history remains a point of controversy.

Marketing Investigations: Novartis has faced regulatory scrutiny over its marketing practices for various products, including investigations into off-label promotion and physician kickback schemes. While no major enforcement actions have been publicly linked specifically to Tasigna, the broader pattern of pharmaceutical marketing investigations has created reputational challenges for the company.